- Obesity affects more than half a billion people worldwide and is a leading risk factor for some of the biggest global drivers of morbidity and mortality, such as heart disease, stroke and type 2 diabetes1
- The new research and development program complements other Boehringer Ingelheim programs that could potentially be used in combination treatments to further improve weight reduction
- Gubra may receive up to € 250 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales
INGELHEIM, Germany & HØRSHOLM, Denmark I September 7, 2017 I Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity. The collaboration will bring together Gubra’s expertise in the design, synthesis, characterization and in in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the development of innovative medicines for patients with cardiometabolic disease. It further expands and complements Boehringer Ingelheim’s comprehensive research and development portfolio in cardiometabolic diseases, one of the company’s core focus areas.
Excessive weight and obesity are amongst the leading risk factors for heart disease, ischemic stroke, liver diseases and type 2 diabetes as well as for a number of cancers. The worldwide prevalence of obesity (BMI ≥30 kg/m2) has nearly doubled between 1980 and 2008. More than half a billion adults worldwide (10% of men and 14% of women) were obese in 2008 and at least 2.8 million people die each year as a result of being overweight or obese.1 There are insufficient treatment options available, resulting in a high unmet medical need for safe and effective treatments that achieve significant weight loss.
The joint research and development program between Boehringer Ingelheim and Gubra aims to identify novel peptidic compounds which are able to regulate food intake. It complements other ongoing Boehringer Ingelheim research and development programs, including the dual acting glucagon/GLP-1 agonist and the long-acting amylin analog development programs conducted in collaboration with Zealand Pharma A/S, Copenhagen, Denmark.2
“We look forward to working with Gubra to bring breakthrough treatments for obesity,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “It underscores our holistic, patient centric research strategy in metabolic diseases, which addresses not only obesity but also diabetes and non-alcoholic steatohepatitis as well as complications like diabetic nephropathy and diabetic retinopathy“.
Boehringer Ingelheim aspires to advance the treatment of cardiometabolic disease and has built a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute stroke and myocardial infarction, hypertension and cardio-renal risk reduction. With its broad research and development approach in cardiometabolic disease, the company aims to develop the next generation of medical innovations in this therapeutic area to positively transform the lives of people with cardiometabolic disease and deliver high value for health care systems.
Henrik Blou, CEO of Gubra ApS said, “We are extremely pleased to enter this collaboration and license agreement with Boehringer Ingelheim, which is yet another proof of the quality of our longstanding work in the metabolic space”. And he adds, “it is truly a pleasure to be able to work with Boehringer Ingelheim on this important project and it enables us to utilize our very broad range of research, discovery and development capabilities for the benefit of the large number of patients suffering from this condition”.
About Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
About Gubra
Founded in 2008, Gubra – an abbreviation for Gut-and-Brain – is a privately-held biotech company located in Denmark delivering scientific counselling, contract research services, and projects for co-development in four main focus areas: Obesity, diabetes, NASH and gastrointestinal disorders. Gubra specializes in in vivo pharmacology, histology, RNA sequencing, bioinformatics and peptide discovery. Gubra delivers preclinical services to our partners by combining cutting-edge technology with our accumulated experience and proven methodology. Additionally, Gubra has several early target and drug discovery programs aimed for partnering. For more information, please visit our website at www.gubra.dk (link is external).
SOURCE: Boehringer Ingelheim
Post Views: 33
- Obesity affects more than half a billion people worldwide and is a leading risk factor for some of the biggest global drivers of morbidity and mortality, such as heart disease, stroke and type 2 diabetes1
- The new research and development program complements other Boehringer Ingelheim programs that could potentially be used in combination treatments to further improve weight reduction
- Gubra may receive up to € 250 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales
INGELHEIM, Germany & HØRSHOLM, Denmark I September 7, 2017 I Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity. The collaboration will bring together Gubra’s expertise in the design, synthesis, characterization and in in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the development of innovative medicines for patients with cardiometabolic disease. It further expands and complements Boehringer Ingelheim’s comprehensive research and development portfolio in cardiometabolic diseases, one of the company’s core focus areas.
Excessive weight and obesity are amongst the leading risk factors for heart disease, ischemic stroke, liver diseases and type 2 diabetes as well as for a number of cancers. The worldwide prevalence of obesity (BMI ≥30 kg/m2) has nearly doubled between 1980 and 2008. More than half a billion adults worldwide (10% of men and 14% of women) were obese in 2008 and at least 2.8 million people die each year as a result of being overweight or obese.1 There are insufficient treatment options available, resulting in a high unmet medical need for safe and effective treatments that achieve significant weight loss.
The joint research and development program between Boehringer Ingelheim and Gubra aims to identify novel peptidic compounds which are able to regulate food intake. It complements other ongoing Boehringer Ingelheim research and development programs, including the dual acting glucagon/GLP-1 agonist and the long-acting amylin analog development programs conducted in collaboration with Zealand Pharma A/S, Copenhagen, Denmark.2
“We look forward to working with Gubra to bring breakthrough treatments for obesity,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “It underscores our holistic, patient centric research strategy in metabolic diseases, which addresses not only obesity but also diabetes and non-alcoholic steatohepatitis as well as complications like diabetic nephropathy and diabetic retinopathy“.
Boehringer Ingelheim aspires to advance the treatment of cardiometabolic disease and has built a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute stroke and myocardial infarction, hypertension and cardio-renal risk reduction. With its broad research and development approach in cardiometabolic disease, the company aims to develop the next generation of medical innovations in this therapeutic area to positively transform the lives of people with cardiometabolic disease and deliver high value for health care systems.
Henrik Blou, CEO of Gubra ApS said, “We are extremely pleased to enter this collaboration and license agreement with Boehringer Ingelheim, which is yet another proof of the quality of our longstanding work in the metabolic space”. And he adds, “it is truly a pleasure to be able to work with Boehringer Ingelheim on this important project and it enables us to utilize our very broad range of research, discovery and development capabilities for the benefit of the large number of patients suffering from this condition”.
About Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
About Gubra
Founded in 2008, Gubra – an abbreviation for Gut-and-Brain – is a privately-held biotech company located in Denmark delivering scientific counselling, contract research services, and projects for co-development in four main focus areas: Obesity, diabetes, NASH and gastrointestinal disorders. Gubra specializes in in vivo pharmacology, histology, RNA sequencing, bioinformatics and peptide discovery. Gubra delivers preclinical services to our partners by combining cutting-edge technology with our accumulated experience and proven methodology. Additionally, Gubra has several early target and drug discovery programs aimed for partnering. For more information, please visit our website at www.gubra.dk (link is external).
SOURCE: Boehringer Ingelheim
Post Views: 33
